Earnings Briefs: Mylan, AbbVie, Vertex, Novo Nordisk, Gilead, Acorda
Executive Summary
Mylan sticks with Abbott deal, confident that it will be a successful tax inversion, while AbbVie rules out similar deals after walking away from Shire upon deciding recent tax policy changes rule out its own inversion play. Other updates from the third-quarter earnings calls, in brief.
You may also be interested in...
Sanofi Says Au Revoir To Viehbacher, But Is It Committing A Faux Pas?
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
Acorda Positions Ampyra For Large Market Of Post-Stroke Deficits
Acorda plans to move Ampyra to Phase III for treating post-stroke deficits, after reporting positive Phase II results. The company also reported a signal from a small proof-of-concept study in cerebral palsy, but next steps are unclear in that indication.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.